Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle of the week is already here, which means there is much to do. No doubt, you can relate on some level. So please join us as we grab a cup of stimulation — we are sticking with maple bourbon for the moment — and tackle the Zoom and Skype calls that are piling up. Meanwhile, here is the latest grab bag of items of interest to help you along. Hope you conquer the world today, such as it is, and do stay in touch …

The Food and Drug Administration released guidance for approving a Covid-19 vaccine, saying the vaccine has to prevent or decrease disease severity in at least 50% of people who are inoculated, Reuters informs us. “The guidelines are pretty standard, they look pretty much like influenza vaccine guidelines,” says Gregory Poland, director of Mayo Vaccine Research Group. “I don’t think that’s a high bar. I think that’s a low to maybe an appropriate bar for a first-generation Covid-19 vaccine.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy